CellVoyant has secured £7.6M in seed funding, bolstering its mission to revolutionize stem cell therapy development using AI. The investment round, spearheaded by Octopus Ventures, drew support from Horizons Ventures, Verve Ventures, and Air Street Capital. This infusion of capital will enable CellVoyant to expand operations and advance its innovative biotechnological pursuits. Patient-centered care stands to benefit significantly from CellVoyant's pioneering work, marking a bright future for medical advancements.